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Abstract. Dengue transmission in Mexico has become a major public health problem. Few epidemiological studies
have examined the seroprevalence of dengue in Mexico, and recent estimates are needed to better understand dengue
transmissiondynamics.Weconducted adengueseroprevalence survey among1,668 individuals including all agegroups
in three urbansettings inYucatan,Mexico.Children (< 19yearsold)were selected randomly fromschools. The adults (³19
years old) were selected from healthcare facilities. Participants were asked to provide a venous blood sample and to
answer a brief questionnaire with demographic information. Previous exposure to dengue was determined using indirect
immunoglobulin G enzyme-linked immunosorbent assay. The overall seroprevalence was 73.6%. The age-specific
seroprevalence increasedwith age, going from51.4% (95%confidence interval [CI] = 45.0–57.9%) in children £ 8 years to
72% (95% CI = 66.3–77.2%) in the 9- to 14-years old. The highest seroprevalence was 83.4% (95% CI = 77–82.2%) in
adults greater than 50 years. The seroprevalence inMerida was 68.6% (95%CI = 65–72%), in Progreso 68.7% (95%CI =
64.2–72.8%), and in Ticul 85.3% (95%CI = 81.9–88.3%). Ticul had the highest seroprevalence in all age groups. Logistic
regression analysis showed that age andcity of residencewere associatedwith greater risk of prior dengue exposure. The
results highlight the level of past exposure to dengue virus including young children. Similar studies should be conducted
elsewhere in Mexico and other endemic countries to better understand the transmission dynamics of dengue.
INTRODUCTION
Dengue is a global public health problem affecting more
than 100 countries, with approximately three billion people at
risk and an estimated 390 million dengue infections annually
worldwide.1 Dengue is one of the vector-borne viral diseases
with high impact throughout the Americas with an average of
1.8 million of dengue cases reported during the current de-
cade.2 Brazil, Colombia, and Mexico account for the largest
burden of disease in the region.3,4
Although dengue epidemics have increased significantly
worldwide,1,5 global estimates of dengue distribution and
disease burden remain imprecise in most dengue endemic
areas.6,7 The real burden of dengue is unknown as most
dengue infections are asymptomatic, misdiagnosed, or not
reported.6 Some of the main issues in dengue surveillance
include the lack of standardized reporting procedures, vari-
able diagnostic laboratory capacity in traditional surveillance
systems, along with the absence of reporting from the private
health sector, which in our study population represents an
important proportion of all healthcare providers.8 An impor-
tant, but underutilized tool in some countries is population-
level dengue antibody surveys. Seroprevalence surveys are
invaluable in identifying the burden of both symptomatic and
asymptomatic infections and quantifying infection prevalence
and incidence in different epidemiological settings.9–13
Although dengue virus (DENV) has been circulating in
Mexico since the late 1970’s, recently there have been lar-
ger and more frequent dengue outbreaks with an increas-
ing proportion of severe cases being reported to the
national epidemiological surveillance system. In addition, co-
circulation of the four serotypes of DENV is being detected
more often since 2010 compared with the previous de-
cades.14 Dengue surveillance in Mexico is conducted pas-
sively through the report of suspected dengue cases by the
doctors in the healthcare facilities. As a result, only a small
fraction of symptomatic cases are diagnosed and reported
through the surveillance system,15 and hospital records only
partially report the incidence of severe dengue cases.16 These
reported cases are likely a small proportion of the total dengue
burden, especially in economically vulnerable communities
that may not be seeking healthcare, and therefore, are expe-
riencing undetected cases of dengue. In addition, there is
scant information regarding the extent of transmission in cities
and suburban areas in Mexico. There is also limited in-
formation regarding the proportion of asymptomatic and mild
infections in the population at large, and potential mis-
diagnosis of dengue as other endemic infections (leptospiro-
sis,17 rickettiosis,18 and the recently introduced chikungunya
virus [2015]19 and Zika virus [2016]20) because of limited
diagnostics.21,22 Despite the known increase in the reported
number of dengue and severe dengue cases,23 there are few
seroprevalence surveys in Mexico. More information is
needed to understand the epidemiology of the disease in
Mexico over the last three decades. One of the regions of
concern with regard to dengue transmission and outbreaks in
Mexico is the state of Yucatan. Dengue transmission has been
documented in Yucatan since 1979, and in the past two de-
cades, there have been large dengue outbreaks and annual
co-circulation of at least two serotypes increasing the severity
of dengue in this area.23 During the early 1990s, the circulation
of DENV serotypes DENV1 and DENV4 was detected, but
DENV3was themost often isolated serotype inYucatan. In the
early 2000s, most of the outbreaks were due to DENV2. Since
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2006, DENV2 has been co-circulating with DENV1 and
DENV4.23
In this article, we present the results of a cross-sectional
dengue serosurvey conducted in three cities in the state of
Yucatan in 2014, as part of a series of baseline studies nec-
essary to better understand dengue transmission dynamics in
three different settings in Yucatan, Mexico. This baseline
dengue seroprevalence information of at risk populations in
Yucatan will allow for the assessment and modeling of the
potential impact of a dengue vaccine9 and will function as a
benchmark to evaluate the effectiveness of different in-
tervention strategies, such as vector control and vaccine in-
troduction, among others.24–29
METHODS
Study settings. The state of Yucatan is located in the
southeastern peninsula of Mexico and borders the Gulf of
Mexico and the Caribbean Sea. We chose to conduct our
study in three cities that exemplify different levels of trans-
mission based on historical epidemiological surveillance data.
We chose a high transmission setting (Merida), a medium
transmission setting (Ticul), and a low transmission setting
(Progreso).30 Merida, the capital city of Yucatan, is the largest
urban center in the region with a population of 814,000 in-
habitants. The weather is warm throughout the year (mean
annual temperature is 25.9C, ranges from 19.5 to 33.6), and
the rainy season occurs from June to October with an annual
precipitation of 1,050 mm. Progreso is the main seaport in the
state, is located32 kmnorthofMerida, andhasapopulation of
54,000 inhabitants. The weather in Progreso is similar to
Merida. Progreso is a destination for national and international
tourists—its population increases during the weekends and
holidays (July–August). Ticul is a rural town located 82 km
south of Merida with 34,000 inhabitants, and the weather is
similar to Merida.
Selection of survey population. Our objective was to es-
timate the overall level of exposure to dengue (asmeasured by
prevalence of antibody to dengue) in populations within the
three study sites in Yucatan, with an emphasis on the younger
population (< 19 year olds) that could be possibly targeted for
vaccination. The desired survey sample size was estimated
based on 50% prevalence and a 95% confidence interval
(95% CI), which suggested a sample size of 1,307 individuals
for our study. We increased the sample size to 1,700 to in-
crease thenumber of children (< 19year olds) in the study (they
comprised half of the samples) and distributed it according to
the population size in the three settings, with a higher pro-
portion of samples coming fromMerida, followed by Progreso
and Ticul.
The sampling scheme included two different approaches.
The first one was a school-based survey with a random se-
lection of schools in the three cities followed by a random
selection of children (5–19 years old) in the selected elemen-
tary, middle, and high schools of Merida, Ticul, and Progreso.
We selected eight schools from Merida (five were elemen-
tary schools), six schools fromProgreso (fourwere elementary
schools), and five schools from Ticul (three were elemen-
tary schools). Prior agreements and an explanation of the
study aims were made with the local ministries of Health and
Education of Yucatan. We requested the lists of students by
grade to obtain ages of the participants and their information.
We did a stratified randomization by grade and school to have
a proportional sample in each age group. We excluded par-
ticipants whose siblings were previously randomized and had
provided signed informed consent. In the city of Merida, we
confined the study to schools in the central metropolitan area.
Blood samples were obtained from students at school after
their parents signed the informed consent forms. The results
of the serosurvey were delivered personally to the parents of
the participating children.
The adults (³ 19 years old) were stratified by age and ran-
domly selected from people attending public primary health-
care centers in Merida, Progreso, and Ticul. We included
individuals who did not have signs of acute febrile illness, who
were requesting a health certificate or were under clinical
follow-up for a noncommunicable disease. Because the sur-
vey sample was not proportional to age and sex of the pop-
ulation in the locality, weightswere calibrated to reproduce the
age distribution of the population in each locality and reduce
sample bias. Blood samples were obtained after the study
participants signed the informed consent forms. For the adult
study participants, their serosurvey results were reported to
them by telephone or home visits.
Study procedures. Participants were asked to provide a
5-mL venous blood sample and to complete a brief ques-
tionnaire with basic demographic information. Blood samples
were collected in anticoagulant-free Vacutainer tubes by
trained and certified health personnel, centrifuged within
1.3 hours of collection, and transported to the state laboratory.
Samples were stored at −70C ± 5C until the serological
testing was done. Serum samples were obtained from indi-
viduals and tested for prior dengue exposure in the state
public health laboratory (LESPRE) of the Ministry of Health.
Prior exposure to dengue was determined by testing for im-
munoglobulin G (IgG) antibody to dengue using Panbio IgG
indirect enzyme-linked immunosorbent assay (ELISA). Stan-
dard cutoff points were used for defining positive (³ 12 Panbio
units) and negative samples (< 9 Panbio units). Samples that
had reading in between these cutoff thresholdswere classified
as “indeterminate.”
Ethical review.This studywasapprovedby the institutional
review boards at Fred Hutchinson Cancer Research Center
and theGeneral Hospital Agustı´nO’Horan of Yucatan.Written
consent was obtained from all adult participants (³ 19 years
old) after providing them with a detailed explanation of the
study and procedures. Parents/guardians of all child partici-
pants (< 19 years old) were asked to provide written consent
on their behalf.
Statistical analysis. Descriptive analysis of the demo-
graphic variables and a logistic regression model analysis
were carried out using R (version 3.2.2).31 Age was grouped
into five categories: £ 8, 9–14, 15–19, 20–49, and ³ 50 years.
We estimated the age-specific dengue antibody preva-
lence and fit a logistic regression model of the variables
independently associated with dengue seropositivity. The
baseline category for the logistic regression was to be dengue
seronegative. The relationship was estimated as the odds
ratio. The independent variables considered were age (£ 8
years old considered as the reference group), gender (male as
the reference group), place of residence (Merida as reference),
previous history of dengue (not having previous history of
dengue as reference), and previous dengue confirmation (no
previous confirmation of dengue as reference).
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RESULTS
Description of the study population. From January
through June 2014, a total of 1,731 serum samples were
collected in the cities of Merida, Progreso, and Ticul. Most of
the samples (43%) were collected in Merida (748), 27% in
Progreso (472), and 30% in Ticul (511). Most of the samples
were obtained from healthcare centers (56%), whereas 24%
were collected fromelementary schools and 20% frommiddle
and high schools. We analyzed 1,667 blood samples from
people from the three cities: Merida (700), Progreso (469), and
Ticul (498). The collected samples were from people distrib-
uted widely through the neighborhoods in the selected cities
(Figure 1). After processing the samples, 3.6% (63/1,731) had
indeterminate results for the IgG ELISA and were excluded
from our analyses.
The mean age in the overall study population was 25.8
years (standard deviation = 18.04), with no significant dif-
ference in the mean population age between the three
surveyed cities (P = 0.172). The population was evenly
distributed by age group, except for the 9 to 14 and 15 to 19
year-old age groups in Progreso as compared withMerida and
Ticul (Table 1). Most of the participants were female (62%),
which is higher than the proportion of females (51%) in
Yucatan. We found significant differences in gender distribu-
tionbetweencities (with somepopulationshavingmore females
sampled; P < 0.01).
The majority of the study population (94%) was born in
Yucatan, with Ticul having a significantly higher proportion
(98%) born in Yucatan as compared with Progreso (93.8%)
and Merida (89.1%) (Table 1). This may be because Ticul is a
rural town, and the inhabitants are less likely to leave the state
(observation by field team in Ticul).
A small proportion of the participants (5%) mentioned
having previous history of dengue. This proportion was higher
in Merida (8.6%), followed by Progreso (3.4%) and Ticul (2%).
We also found that a small proportion (2.8%) of the study
population recalled havingprevious laboratory confirmationof
dengue, andmost of these confirmed caseswere fromMerida
(3.9%), potentially because as the capital of Yucatan, acces-
sibility to health care is highest inMerida as comparedwith the
other twocities. Theproportionof laboratory confirmationwas
higher in the adult population.
Dengue seroprevalence. The overall estimated dengue
antibody prevalence in Yucatan was 73.6% (95% CI =
71.4–75.7%), indicating previous dengue exposure in most of
the population. Dengue seroprevalence in the Yucatan in-
creased with age in all three study settings (Figure 2).
Overall, children £ 8 years old had the lowest seroprevalence
(51.4% [95% CI = 45–57.9%]) and adults ³ 50 years old had
the highest seroprevalence (83.4% [95% CI = 77–88.2%])
(Figure 2A).
The seroprevalence was highest in the Ticul population
(85.3% [95% CI = 81.9–88.3%]) and was similar in the other
two cities (Merida: 68.6% [95% CI = 65–72%] and Progreso:
68.7% [95% CI = 64.2–72.8%]). The estimated dengue sero-
prevalence in Merida ranged from 43.6% (95% CI =
33.7–53.8%) in £ 8-year-old children to 79.8% (95% CI =
69.9–87.6%) in ³ 50-year-old adults (Figure 2B). In Progreso,
the seroprevalence ranged from45.1% (95%CI = 33.2–57.3%)
in the younger age group (£ 8-year olds) to 71.4% (95% CI =
56.7–83.4%) in the ³ 50-year-old (Figure 2C) group. Ticul had
the highest dengue seroprevalence in all age groups compared
with the other two cities; it ranged from 69.6% (95% CI =
57.3–80.1%) in £ 8-year olds to 95.9% (95%CI = 88.5–99.1%)
in ³ 50-year olds (Figure 2D).
Our logistic regression model showed that there were sig-
nificant relationships between being positive for dengue an-
tibody and increased age. The reference group for age was
the £ 8 years old group. The 9–14 year old group had 2.43
(95% CI = 1.69–3.50) times the odds of being seropositive
compared with the reference group (Table 2). The ³ 50 years
group had 4.74 (95% CI = 3.08–7.46) times the odds of being
seropositive comparedwith the reference group. Females had
1.27 (95% CI = 1.02–1.59) times the odds of being sero-
positive compared with males. Participants from Ticul had
2.67 (95% CI = 1.99–3.60) times the odds of being sero-
positive compared with the participants from Merida.
The characteristics of: being born in Yucatan, self-reported
history of previous infections with dengue and self-reported
previous confirmation of dengue were not associated with
seropositivity (Table 2).
FIGURE 1. Geographic location of the participants in the seroprevalence study. (A) Geographic location of participants from Merida, (B) Geo-
graphic location of participants from Progreso, and (C) Geographic location of participants from Ticul. The red dots show dengue seropositive
individuals and green the seronegatives. This figure appears in color at www.ajtmh.org.
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DISCUSSION
Our study found an overall dengue antibody prevalence of
73.6% in our surveyed cities in Yucatan, consistent with pre-
vious studies in this area. In contrast to previous studies, we
found that women had a higher dengue antibody prevalence
than males. In addition, we found that Ticul, a city previously
classified as an area with a medium level of dengue trans-
mission, had the highest prevalence of previously exposed
individuals (85.3% versus ∼68% in the other surveyed cities),
and this observation held when comparing all the surveyed
age groups. More than 70% of children in the age group be-
tween 9 and 14 years had been exposed to dengue, which has
important implications to help targeting dengue vaccines and
maximizing future vaccine impact.
Our survey is the most recent cross-sectional study in the
state of Yucatan (first survey was in 1985), and our overall
prevalence was similar to other dengue serosurveys carried
out in Mexico and the Yucatan.32 In 1985, the prevalence of
anti-dengue antibodies in the urban population of Yucatan
was 72.5%, very similar to our overall seroprevalence esti-
mates.33 Another study in a cohort of school children from8 to
14 years old (1987–1988) including urban and rural localities of
Merida reported anoverall dengue seroprevalenceof 56.3% in
children living in urban areas comparedwith 63.7% in children
living in rural areas.34 Comparing these results from almost
TABLE 1
Demographic characteristics of the study population in Yucatan, Mexico (N = 1,667)
Merida Progreso Ticul Total
n Percent n Percent N Percent n Percent
Age (years)
£ 8 101 14.5 71 15.1 69 13.8 241 14.5
9–14 90 12.8 110 23.4 75 15.0 275 16.5
15–19 128 18.3 64 13.6 93 18.7 285 17.0
20–49 292 41.7 175 37.5 188 37.8 655 39.3
50+ 89 12.7 49 10.4 73 14.7 211 12.7
Sex
Male 291 41.5 157 33.1 184 36.9 632 37.9
Female 409 58.5 312 66.9 314 63.1 1,035 62.1
Born in Yucatan
Yes 624 89.1 440 93.8 487 97.8 1,551 94.0
No 76 10.9 29 6.2 11 2.2 116 7.0
History of previous dengue
Yes 60 8.6 16 3.4 10 2.0 86 5.2
No 640 91.4 453 96.6 488 98.0 1,581 94.8
Previous confirmation of dengue
Yes 27 3.9 12 2.6 8 1.6 47 2.8
No 673 96.1 457 97.4 490 98.4 1,620 97.2
FIGURE 2. Dengue seroprevalence to indirect immunoglobulin G (IgG) by age group and city, Yucatan, Mexico 2014. (A) Overall dengue
seroprevalence; (B) Dengue seroprevalence, Merida; (C) Dengue seroprevalence, Progreso; and (D) Dengue seroprevalence, Ticul. This figure
appears in color at www.ajtmh.org.
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20 years ago with our current prevalence estimate for Merida
(68.8%), one can conclude that Merida has a stable (endemic)
dengue transmission pattern. More recent studies have found
an overall dengue antibody prevalence in Yucatan of 59.9%
and 81.5% in 1996 and 2006 respectively.35When comparing
our results with other Latin American countries with endemic
dengue, our estimates were similar to those from Venezuela
and Brazil but lower than those from Nicaragua.22,36–38
In our study, women were more likely to be antibody pos-
itive compared with men. Previously, cases reported to the
surveillance system indicated that there was a similar expo-
sure pattern of women (51%) and men (49%) to dengue.34
Our sample population was 59% female, which may be why
we saw this difference. However, the prevalence rates from
the public health surveillance system only captures symp-
tomatic cases that attend a healthcare facility, which likely
greatly underestimates the overall level of dengue exposure.
Therefore, our observed pattern may be related to dengue
transmission patterns—there may be more dengue trans-
mission within a household setting, and women in Yucatan
are more likely to stay at home compared with men. Addi-
tional community or population-based antibody surveys are
necessary to better clarify this relationship of dengue expo-
sure and sex.
We found that there was a statistically significant relation-
ship between age and exposure to dengue, with older age
classes showing higher levels of exposure than younger age
classes. The other variables tested were not significantly as-
sociated with seropositivity in the study population. In our
study, around half of the younger children (£ 8 years old) were
antibody positive to dengue, whereas more than 80% of
adults > 50 years old were positive for dengue antibody. The
overall dengue antibody prevalence in children and adoles-
cents 9–14 years old was 72%. This is a relevant finding given
the World Health Organization (WHO) recommendations for
introduction of the first dengue vaccine that is also licensed in
Mexico (CYD-TDV-Dengvaxia).39 This vaccine was licensed
targeting the population from 9 to 45 years old. The WHO
recommends introducing the dengue vaccine (Dengvaxia)
only in geographic settings where epidemiological data sug-
gest a high burden of disease (seroprevalence ³ 70%) in the
populations to be targeted for vaccination to maximize pub-
lic health impact and cost-effectiveness.39,40 This high bur-
den can be objectively measured by dengue seroprevalence
surveys.
Ticul had the highest seroprevalence in all age groups. This
may be a result of a recent DENV1 outbreak in 2013 there. The
similar prevalence estimates of Merida and Progreso are as-
sociated with an endemic transmission pattern. The varied
exposure patterns among the populations from the three
surveyed urban areas indicate that there is heterogeneous
dengue transmission across Yucatan.
Oneof themain limitations of this study is the lack of dengue
serotype–specific prevalence information and the reliance on
IgG ELISA without neutralizing assays for confirmation or for
serotyping. Identifying serotypes could help better un-
derstand the intensity of transmission and establish whether
the overall population or specific age groups have been ex-
posed to and the level of exposure to one or more serotypes.
This serosurveywasconductedbefore the introductionof Zika
virus to Mexico, so we are confident that the ELISA results
were not cross-reacting with other flaviviruses. Our sampling
strategy focused on enrolling adults in the healthcare centers
and intentionally oversampled the population < 19 years old
because this particular group is the potential target vaccina-
tion group in Mexico, so it is not a true random sample of the
population. Aswith all self-reported health histories, therewas
likely some recall bias when interviewing people about having
had dengue. As this survey was conducted in school children
and adults attending public health services provided by the
Ministry of Health, these individuals likely are fromhouseholds
of lower-and middle socioeconomic status.
As established by the Mexican Dengue Expert Group, it is
essential to develop an evidence-based proactive strategy
TABLE 2
Logistic regression model of risk factors associated with dengue seropositivity in Yucatan, Mexico
Variables Total (N = 1,667) Seropositives (N = 1,227) Seronegatives (N = 440) Odds ratio 95% CI
Age (years)
< 8 241 (14.5) 124 (10.1) 117 (26.6) Ref Ref
9–14 275 (16.5) 198 (16.1) 77 (17.5) 2.43 1.69–3.50
15–19 285 (17.0) 209 (17.0) 76 (17.2) 2.59 1.81–3.75
20–49 655 (39.3) 520 (42.4) 135 (30.7) 2.63 2.65–4.99
50+ 211 (12.7) 176 (14.3) 35 (8.0) 4.74 3.08–7.46
Sex
Male 632 (37.9) 445 (36.3) 184 (42.0) Ref Ref
Female 1,035 (62.1) 781 (63.7) 254 (58.0) 1.27 1.02–1.59
City
Merida 700 (42.0) 480 (39.1) 220 (50.0) Ref Ref
Progreso 469 (28.1) 322 (26.2) 147 (33.4) 1.01 0.78–1.29
Ticul 498 (29.9) 425 (34.7) 73 (16.6) 2.67 1.99–3.60
Born in Yucatan
No 116 (6.9) 77 (6.3) 39 (8.9) Ref Ref
Yes 1,551 (93.1) 1,150 (93.7) 401 (91.1) 1.45 0.96–2.16
History of previous dengue
No 1,581 (94.9) 1,163 (94.8) 418 (95.2) Ref Ref
Yes 86 (5.1) 64 (5.2) 21 (4.8) 1.09 0.67–1.86
Previous confirmation of dengue
No 1,620 (97.2) 1,190 (97.0) 428 (97.3) Ref Ref
Yes 47 (2.8) 37 (3.0) 12 (2.7) 1.25 0.64–2.70
CI = confidence interval.
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that provides evidence to decision makers for the intro-
duction of dengue vaccines.41 These data should include re-
sults from clinical trials, epidemiological studies, and better
burden of disease estimates to create a sustainable immuni-
zation programwith all the resources required for the adoption
of the new vaccine and future evaluation of its impact and
effectiveness.41 Our survey provides evidence regarding the
serological status of potential target populations in a highly
endemic region of the country. Population-based sero-
surveys, similar to ours, are extremely important to iden-
tify age groups with higher dengue risk and to best target
interventions.10,11,27,42–44 Similar dengue serosurveys should
bepursuedelsewhere inMexicoandotherendemiccountries to
better understand the transmission dynamics of dengue and to
help evaluate and model the impact of the vaccines and other
interventions already available and in development.9,29,44–49
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